

## Disclosures

### Personal Commercial (22)

Company Name	Relationship Category	Compensation Level	Topic Area(s)
<i>Self</i>			
AstraZeneca Pharmaceuticals	Consultant Fees/Honoraria	Significant ( $\geq$ \$5,000)	General Cardiology
Bayer Healthcare Pharmaceuticals	Research/Research Grants ‡ Galileo	None (\$0)	Invasive CV Angio and Interventions
Bayer Healthcare Pharmaceuticals	Other - Lecture honoraria	Modest ( $<$ \$5,000)	Invasive CV Angio and Interventions
Biosensors	Consultant Fees/Honoraria	Significant ( $\geq$ \$5,000)	Invasive CV Angio and Interventions
ControlRad	Other - Stock options ( $<$ 1%)	Modest ( $<$ \$5,000)	Invasive CV Angio and Interventions
Daichi-Sankyo	Consultant Fees/Honoraria	Modest ( $<$ \$5,000)	Valvular Heart Disease
Daiichi Sankyo	Research/Research Grants ‡ ENVISAGE-AF	None (\$0)	General Cardiology
Medtronic	Research/Research Grants ‡ SPYRAL, COREVALVE	None (\$0)	Invasive CV Angio and Interventions
Philips	Consultant Fees/Honoraria	Significant ( $\geq$ \$5,000)	Invasive CV Angio and Interventions
<i>Spouse/Domestic Partner</i>			
Abbott Vascular	Consultant Fees/Honoraria	Significant ( $\geq$ \$5,000)	Invasive CV Angio and Interventions
Astra-Zeneca	Research/Research Grants ‡ TWILIGHT	None (\$0)	General Cardiology
Boston Scientific Corporation	Consultant Fees/Honoraria	Modest ( $<$ \$5,000)	Invasive CV Angio and Interventions
Claret	Other - Stock Options liquidation	Significant ( $\geq$ \$5,000)	Invasive CV Angio and Interventions
CSL Behring	Consultant Fees/Honoraria	Modest ( $<$ \$5,000)	General Cardiology
Elixir	Other - Stock options ( $<$ 1%)	Modest ( $<$ \$5,000)	Invasive CV Angio and Interventions
Merck & Co., Inc.	Consultant Fees/Honoraria	Modest ( $<$ \$5,000)	General Cardiology
Philips	Consultant Fees/Honoraria	Modest ( $<$ \$5,000)	Invasive CV Angio and Interventions
Sanofi-Aventis	Consultant Fees/Honoraria	Significant ( $\geq$ \$5,000)	General Cardiology
Siemens	Consultant Fees/Honoraria	Modest ( $<$ \$5,000)	Invasive CV Angio and Interventions
Siemens	Consultant Fees/Honoraria	Modest ( $<$ \$5,000)	Invasive CV Angio and Interventions
Spectranetics	Consultant Fees/Honoraria	Modest ( $<$ \$5,000)	Invasive CV Angio and Interventions
WebMD	Other - teaching/lectures/interviews	Modest ( $<$ \$5,000)	Invasive CV Angio and

## Personal Non-Commercial (2)

Non-Commercial Entity Name	Relationship Category	Compensation Level	Topic Area(s)
<i>Self</i>			
CardioVascular Research Foundation	Other - <i>Physician faculty</i>	None (\$0)	<i>Invasive CV Angio and Interventions</i>
SCAI	Other - <i>physician faculty</i>	None (\$0)	<i>Invasive CV Angio and Interventions</i>

## Clinical Trial Enroller (13)

Trial Name	Trial Sponsor	Trial Funding Source
Graftmaster	Abbott	
COAPT trial	Abbott	
Triluminate	Abbott Laboratories	
Global cVCAD registry	Abiomed	
Bioflow-V	Biotronik	
shield	CellAegis US, Inc	
ACT-Indorsia	Indorsia Pharmaceuticals	
Cell Based therapy in CHF	Juventas	
Intrepid/APOLLO	MEDTRONIC	
Spyral	MEDTRONIC	
Corevalve Evolut-R Low Risk	MEDTRONIC	
APOLLO/Intrepid	MEDTRONIC	
Renalguard	Renalguard	

## Institutional Financial Decision-Making Role (0)

No disclosures on record

## Expert Witness Testimony (4)

Year	Case Title	Represented	Description	Compensation
<i>Self</i>				
2019	TEVAR repair complication	Defendant † <i>RRD law firm</i>	paraplegia after TEVAR	Significant (>= \$5,000)
2018	Endovascular intervention	Defendant † <i>Brown &amp; James Law firm</i>	GI bleed and death after thrombolytic therapy	Significant (>= \$5,000)
2018	Advanced CHF with aortic stenosis	Defendant † <i>Donahue, Durham and Noona, PC, Guilford, CT</i>	Referral for heart transplant or TAVR	Significant (>= \$5,000)
2018	Angiographic review of CAD	Defendant † <i>MLMIC</i>	Question of underestimation of CAD severity on angiogram in relation to subsequent sudden death within few months of this test.	Significant (>= \$5,000)

† Commercial Funding Source | ‡ Trial Name

## Agreement

Certified Education Attestation | Signed on 11/3/2018

URL for full agreement: <http://disclosures.acc.org/Public/Definition/CertifiedEducationAttestationAgreement>

Confidentiality, Disclosure and Assignment Agreement | Signed on 11/3/2018

URL for full agreement: <http://disclosures.acc.org/Public/Definition/ConfidentialityDisclosureandAssignmentAgreement>

### **ACC and Disclosures**

ACC is committed to ensuring balance, independence, objectivity, and scientific rigor in their governance, programmatic, educational, chapter, and other activities. Fulfilling this commitment depends on member and public confidence in the College's integrity and objectivity. The College recognizes that the activities of College members in their practice, research, and other volunteer and private endeavors could lead to the development of conflicts of interest. Therefore, the College has established a Disclosure Policy and conflict of interest management process as appropriate. All members involved in College governance, including all committees and task forces, programmatic, certified educational, chapter, and other activities must provide complete, timely, accurate, and signed disclosure statements. Compliance with this process is mandatory for participation in College activities.